Drug intelligence / Profile preview

docetaxel + Pivanex

Development stage: Unknown
Lead developer: Titan Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

The combination of docetaxel and Pivanex is an investigational therapy for advanced non-small cell lung cancer (NSCLC). Docetaxel is a taxane chemotherapy agent that stabilizes microtubules, inhibiting cell division. Pivanex (pivaloyloxymethylbutyrate) is a histone deacetylase inhibitor that induces tumor cell differentiation and/or apoptosis. Preclinical studies have shown synergy between these agents in growth inhibition of NSCLC cell lines and improved survival in animal models. Clinical trials have demonstrated the combination to be well tolerated with promising activity in patients with advanced NSCLC[1][2][5].

Brand names: Pivanex
Other names: docetaxel plus Pivanexdocetaxel and Pivanex

Targets

HDAC (HDAC family)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + Pivanex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + Pivanex.

Explore the full profile